MIMs’ platform integrates our MIMsight Knowledge Base—which combines billions of data points and other information extracted from scientific literature, public databases, and multi-omic and clinical patient data-and our proprietary GI² (Genetic Interaction Graph Inference) algorithm inferring genetic interactions within patient tumours and immune systems. These vivid human cartographies of individual patients deliver previously unimagined levels of precise insight used to classify patients into subgroups, identify their molecular and clinical characteristics, predict their response to new therapies, and identify powerful therapeutic targets and biomarkers.

With MIMs’ SaaS product for indication prioritization and biomarker discovery in oncology, you and your team can:

1. Access scientific insights to support strategic decisions on indication prioritization at the pre-clinical stage

2. Increase the success rate of clinical trials for new targeted and immune therapies
3. Explore new potent combined therapies

4. Accelerate early high-value biomarkers to accelerate companion test development

Featured in an article of Lien Multimedia par Sophie Bernard:

Featured in an article of Lien Multimedia par Sophie Bernard:

FounderFuel 2017 : Avec MIMs, la recherche post-génomique s’accélère.http://www.lienmultimedia.com/spip.php?article60540

FounderFuel 2017 : Avec MIMs, la recherche post-génomique s’accélère.
http://www.lienmultimedia.com/spip.php?article60540